In talks with MNCs pharma cos for acquisition of brands: Bafna pharma
Pharmaceuticals formulations major Bafna Pharmaceuticals Ltd was in advanced stage of discussion with some multi-national pharma companies for acquisitions of brands, a company official said.
Bafna Pharmaceuticals Ltd - 532989 - Outcome of Board Meeting (Rights Issue)
Bafna Pharmaceuticals Ltd has informed BSE regarding Outcome of Board Meeting held on November 12, 2021. BAFNA PHARMACEUTICALS LTD. - 532989 - Announcement under Regulation 30 (LODR)-Raising of Funds
3. Raising of funds by way of offer and issue of equity shares to the existing shareholders of the Company on a rights basis (Rights Issue) for an aggregate amount upto INR 50 Crore. The Board has constituted a Rights Issue Committee of Directors for the above purpose and has authorised the Committee to determine the terms of the Rights Issue including the quantum of issue, rights entitlement ratio, issue price, issue size, book closure or record date, entitlement timing of the issue, appointment of intermediaries, etc., in consultation with the Lead Manager to the Right Issue and to decide all other matters relating to the Right Issue. Such details shall be informed and/or announced in due course as and when decided or required, as per applicable statutory provisions and depending upon the market conditions. The above proposal to issue of shares shall be subject to necessary approvals, confirmations and consents as may be necessary and in compliance with applicable law including Bafna Pharmaceuticals Ltd - 532989 - Result For The Half Year Ending 30Th Sep 2021
1. Approved the un - audited financial results of the Company for the quarter /half year ended September 30, 2021. Please find attached Limited Review Report from the Statutory Auditor. 2. Statutory Auditors comments along with Management's Reply: BAFNA PHARMACEUTICALS LTD. - 532989 - Result For The Half Year Ending 30Th Sep 2021
1. Approved the un - audited financial results of the Company for the quarter /half year ended September 30, 2021. Please find attached Limited Review Report from the Statutory Auditor. 2. Statutory Auditors comments along with Management's Reply: BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Outcome for Outcome Of Board Meeting
Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, ('Listing Regulations') as amended, this is to inform you that the Board of Directors ('Board') of the Company, had at its meeting held today i.e. Friday, November 12, 2021, the Board has decided the following matters: 1. Approved the un - audited financial results of the Company for the quarter /half year ended September 30, 2021. Please find attached Limited Review Report from the Statutory Auditor. 2. Statutory Auditors comments along with Management's Reply: 3. Raising of funds by way of offer and issue of equity shares to the existing shareholders of the Company on a rights basis (Rights Issue) for an aggregate amount upto INR 50 Crore. BAFNA PHARMACEUTICALS LTD. - 532989 - Update on board meeting
BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2021 ,inter alia, to consider and approve In continuation to prior intimation of meeting of Board of Directors dated November 03, 2021 and in accordance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, notice is hereby given that at the meeting of the Board of Directors of the Company to be held on Friday, November 12, 2021 shall inter alia also consider the following business: 1. To consider and approve the proposal for various avenues for raising funds, including and in particular Rights Issue to meet capital requirements of the Company. Please take note of the same in your record and acknowledge the receipt of the same. BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Intimation for Quarterly Results And General
BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2021 ,inter alia, to consider and approve Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Friday, 12th November 2021 online through video conferencing, to inter alia consider and adopt un-audited financial results for the quarter and six months ended 30th Sep 2021 and any other business with the permission of the Chair Bafna Pharmaceuticals Ltd - 532989 - Statement Of Investor Complaints For The Quarter Ended September 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- JITENDRA KUMAR PALDesignation :- Company Secretary and Compliance Officer BAFNA PHARMACEUTICALS LTD. - 532989 - Shareholding for the Period Ended September 30, 2021
Bafna Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly Click here